Analyst Research Report Snapshot


Astellas Pharma Inc.




MarketLine (a Datamonitor Company)


08 Apr 2014





Companies referenced:


Available for Immediate Download

Astellas Pharma Inc. - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings, detailed financials, and corporate actions, providing a 360° view of the company. Features: - Detailed information on Astellas Pharma Inc. required for business and competitor intelligence needs - A study of the major internal and external factors affecting Astellas Pharma Inc. in the form of a SWOT analysis - An in-depth view of the business model of Astellas Pharma Inc. including a breakdown and examination of key business segments - Five-year financial information and charts, including balance sheet, income statement, cash flows, market capitalization and multiples, and key ratios for Astellas Pharma Inc. - Intelligence on Astellas Pharma Inc.nv’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors - News about Astellas Pharma Inc., such as business expansion, restructuring, and contract wins - Large number of easy-to-grasp charts and graphs that present important data and key trends Highlights: Astellas Pharma (Astellas or 'the company') is engaged in the manufacture, marketing, import and export of pharmaceuticals and related products. The company operates in Japan, other Asian countries, the Americas, Europe and other regions of the world. It is headquartered in Tokyo, Japan and employed 17,085 people as of March 31, 2012. The company recorded revenues of JPY969,387 million ($12,311.2 million*) during the financial year ended March 2012 (FY2012), an increase of 1.6% over FY2011. The operating profit of the company was JPY131,519 million ($1,670.3 million*) in FY2012, an increase of 10.4% over FY2011. The net profit was JPY78,230 million ($993.5 million*) in FY2012, an increase of 15.6% over FY2011. *Calculated using a constant conversion rate of JPY1 = $0.0127 for the financial year ended March 31, 2012. Reasons to Purchase: - Gain understanding of Astellas Pharma Inc. and the factors that influence its strategies - Track strategic initiatives of the company and latest corporate news and actions - Assess Astellas Pharma Inc. as a prospective partner, vendor or supplier - Support sales activities by understanding your customers' businesses better - Stay up to date on Astellas Pharma Inc.’s business structure, strategy and prospects

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.